Free Trial

Intuitive Surgical (ISRG) Stock Forecast & Price Target

Intuitive Surgical logo
$571.44 -12.61 (-2.16%)
As of 11:53 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Intuitive Surgical - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
2
Buy
15

Based on 18 Wall Street analysts who have issued ratings for Intuitive Surgical in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 18 analysts, 1 has given a sell rating, 2 have given a hold rating, and 15 have given a buy rating for ISRG.

Consensus Price Target

$583.83
2.17% Upside
According to the 18 analysts' twelve-month price targets for Intuitive Surgical, the average price target is $583.83. The highest price target for ISRG is $711.00, while the lowest price target for ISRG is $375.00. The average price target represents a forecasted upside of 2.17% from the current price of $571.44.
Get the Latest News and Ratings for ISRG and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Intuitive Surgical and its competitors.

Sign Up

ISRG Analyst Ratings Over Time

TypeCurrent Forecast
1/28/24 to 1/27/25
1 Month Ago
12/29/23 to 12/28/24
3 Months Ago
10/30/23 to 10/29/24
1 Year Ago
1/28/23 to 1/28/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
15 Buy rating(s)
15 Buy rating(s)
14 Buy rating(s)
16 Buy rating(s)
Hold
2 Hold rating(s)
3 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$583.83$554.17$513.74$371.60
Forecasted Upside2.17% Upside3.61% Upside-0.50% Downside-0.84% Downside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

ISRG Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ISRG Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Intuitive Surgical Stock vs. The Competition

TypeIntuitive SurgicalMedical CompaniesS&P 500
Consensus Rating Score
2.78
2.82
2.52
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside-0.04% Downside13,352.28% Upside11.51% Upside
News Sentiment Rating
Positive News

See Recent ISRG News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/24/2025Truist Financial
2 of 5 stars
Richard Newitter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$640.00 ➝ $666.00+13.37%
1/24/2025Raymond James
4 of 5 stars
Jayson Bedford
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$560.00 ➝ $688.00+17.20%
1/24/2025Piper Sandler
2 of 5 stars
Adam Maeder
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$538.00 ➝ $670.00+14.12%
1/24/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Larry Biegelsen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$630.00 ➝ $687.00+18.38%
1/24/2025Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Joanne Wuensch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$640.00 ➝ $711.00+16.81%
1/24/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Robbie Marcus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$575.00 ➝ $675.00+10.90%
12/5/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$525.00 ➝ $610.00+11.22%
12/2/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeEqual Weight ➝ Overweight$522.00 ➝ $650.00+19.93%
11/26/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$535.00 ➝ $561.00+3.85%
11/19/2024Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
10/18/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
David Roman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target$604.00+15.73%
10/18/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMarket Perform ➝ Market Perform
10/18/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingCautious ➝ Cautious
10/18/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Shagun Singh
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$525.00 ➝ $555.00+8.40%
10/17/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Anthony Petrone
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Target$440.00 ➝ $500.00+5.30%
10/17/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$489.00 ➝ $502.00+5.72%
10/17/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$503.00 ➝ $565.00+18.98%
8/2/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Ridley-Day
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$380.00 ➝ $510.00+13.10%
7/18/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$430.00 ➝ $490.00+17.49%
4/19/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$365.00 ➝ $375.00+0.64%
11/17/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$318.00+4.62%
10/19/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$385.00 ➝ $314.00+14.82%
5/31/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$350.00 ➝ $365.00+18.87%
4/19/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold$245.00 ➝ $290.00-4.27%
4/19/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$300.00 ➝ $315.00+16.98%
3/23/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
B. Vazquez
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 11:53 AM ET.


Should I Buy Intuitive Surgical Stock? ISRG Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, January 27, 2025. Please send any questions or comments about these Intuitive Surgical pros and cons to contact@marketbeat.com.

Intuitive Surgical
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Intuitive Surgical, Inc.:

  • Intuitive Surgical, Inc. has a strong market position with its da Vinci Surgical System, which is widely recognized for enabling complex surgeries through minimally invasive techniques, potentially leading to better patient outcomes and lower recovery times.
  • The company has recently expanded its offerings with the Ion endoluminal system, which allows for minimally invasive biopsies in the lung, indicating a commitment to innovation and addressing broader healthcare needs.
  • As of now, the stock price is approximately $511.63, reflecting a significant interest from investors and a stable valuation within the healthcare equipment sector.
  • Institutional investors hold a substantial 83.64% of the company's stock, suggesting strong confidence in the company's future performance and stability.
  • Recent insider trading activity, including the CEO's sale of shares, can indicate strategic financial management, although it may also raise questions about future performance; however, the overall trend of institutional investment remains positive.

Intuitive Surgical
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Intuitive Surgical, Inc. for these reasons:

  • Insider selling, such as the CEO's recent sale of over 18,000 shares, may signal a lack of confidence in the stock's short-term performance, which could concern potential investors.
  • The stock has experienced significant fluctuations, with a one-year low of $364.17 and a high of $616.00, indicating volatility that may deter risk-averse investors.
  • Despite strong institutional ownership, the fact that only 0.90% of the stock is owned by company insiders could suggest a lack of alignment between management and shareholder interests.
  • Recent market trends in the healthcare sector may pose challenges, as increased competition and regulatory changes could impact the company's growth and profitability.
  • The company's reliance on a few key products, such as the da Vinci Surgical System, may expose it to risks if market demand shifts or if new technologies emerge.

ISRG Forecast - Frequently Asked Questions

According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for Intuitive Surgical is $583.83, with a high forecast of $711.00 and a low forecast of $375.00.

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Intuitive Surgical in the last year. There is currently 1 sell rating, 2 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ISRG shares.

According to analysts, Intuitive Surgical's stock has a predicted upside of 2.17% based on their 12-month stock forecasts.

Over the previous 90 days, Intuitive Surgical's stock had 2 upgrades by analysts.

Intuitive Surgical has been rated by research analysts at BTIG Research, Citigroup, Erste Group Bank, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, Raymond James, Stifel Nicolaus, Truist Financial, and Wells Fargo & Company in the past 90 days.

Analysts like Intuitive Surgical less than other "medical" companies. The consensus rating score for Intuitive Surgical is 2.78 while the average consensus rating score for "medical" companies is 2.82. Learn more on how ISRG compares to other companies.


This page (NASDAQ:ISRG) was last updated on 1/27/2025 by MarketBeat.com Staff
From Our Partners